Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine

doi:10.1016/j.metabol.2004.06.026

Metabolism

Volume 53, Issue 12, December 2004, Pages 1574-1579

https://doi.org/10.1016/j.metabol.2004.06.026 Get rights and content

Abstract

We investigated the levels of asymmetric dimethylarginine (ADMA), an important endogenous inhibitor of nitric oxide (NO), as related to metabolic risk factors known to contribute to atherosclerotic disease. Dimethylarginines were analysed in a cross-sectional study of 563 elderly high-risk men (70 ± 6 years). ADMA and the l-arginine/ADMA (l-arg/ADMA) ratio were highly significantly correlated with several metabolic risk factors. However, only the association with body mass index (BMI) remained significant after adjustment for inter-related variables. When analyzing the results according to being overweight or not, ADMA levels were independently significantly higher (P = .05) and the l-arg/ADMA ratios were significantly lower (P < .008) in individuals with high BMI (≥26 kg/m², median value) as compared with subjects with low BMI. ADMA levels were furthermore significantly lower (P = .037) and l-arginine and the l-arg/ADMA ratios were significantly higher (P = .004 and P = .001, respectively) in smokers compared with nonsmokers, the latter being independent of other risk factors. The strong relationship found between BMI and plasma levels of ADMA and the l-arg/ADMA ratio indicate a link to endothelial dysfunction in overweight subjects. The beneficial dimethylarginine profile observed in smokers in this elderly population is not easily explainable and should be further investigated.

Section snippets

Study design and study population

This is a follow up study of participants from the Oslo Diet and Anti-smoking study performed 1972 to 1977,21 comprising 1,232 men with hypercholesterolemia (total cholesterol > 6.45 mmol/L, 80% smokers). The survivors of this population were 25 years later invited to participate in the Diet and Omega-3 Intervention Trial on Atherosclerosis (DOIT), a 3-year intervention trial aimed at investigating the effects of omega-3 fatty acid supplementation and/or dietary intervention on markers of

Results

Clinical characteristics, use of medication and laboratory variables for the total study population are presented in Table 1. As can be seen, 28% had CVD, 15% had diabetes, 34% were current smokers, 30% had treated hypertension, and 27% were statin users.

Discussion

In the present study of 563 elderly men with high risk for coronary heart disease, we could show a close relationship between BMI and plasma levels of ADMA and the l-arg/ADMA ratio, independent of other metabolic risk factors. Overweight and obese subjects had significantly elevated ADMA levels and lower l-arg/ADMA ratio as compared with lean or normal individuals. Surprisingly, smokers, comprising 34% of the population, and with a smoking history of at least 25 years, had lower levels of ADMA

References (44)

A. Wolf et al.
Dietary l-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans
J Am Coll Cardiol
(1997)
R.H. Boger et al.
The l-arginine-nitric oxide pathwayRole in atherosclerosis and therapeutic implications
Atherosclerosis
(1996)
C. Zoccali et al.
Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal diseaseA prospective study
Lancet
(2001)
S.M. Bode-Boger et al.
Elevated l-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary l-arginine in hypercholesterolemic rabbits
Biochem Biophys Res Commun
(1996)
F. Abbasi et al.
Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus
Am J Cardiol
(2001)
H.M. Eid et al.
Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic diseaseEffects of pravastatin
Atherosclerosis
(2003)
P. Lundman et al.
Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine
J Am Coll Cardiol
(2001)
I. Hjermann et al.
Effect of diet and smoking intervention on the incidence of coronary heart diseaseReport from the Oslo Study Group of a randomised trial in healthy men
Lancet
(1981)
M. Usui et al.
Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure
Life Sci
(1998)
C. Zoccali et al.
Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients
Kidney Int
(2002)

S.B. Williams et al.

Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus

J Am Coll Cardiol

(1996)

R.H. Boger et al.

Dietary l-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbitsComparison with lovastatin

Circulation

(1997)

U.C. Garg et al.

Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells

J Clin Invest

(1989)

P. Kubes et al.

Nitric oxideAn endogenous modulator of leukocyte adhesion

Proc Natl Acad Sci USA

(1991)

P. Vallance et al.

Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure

Lancet

(1992)

J. Leiper et al.

Biological significance of endogenous methylarginines that inhibit nitric oxide synthases

Cardiovasc Res

(1999)

R.H. Boger et al.

LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cellsInvolvement of S-adenosylmethionine-dependent methyltransferases

Circ Res

(2000)

K.Y. Lin et al.

Impaired nitric oxide synthase pathway in diabetes mellitusRole of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase

Circulation

(2002)

S.M. Bode-Boger et al.

Oral l-arginine improves endothelial function in healthy individuals older than 70 years

Vasc Med

(2003)

R.H. Boger et al.

Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction: Its role in hypercholesterolemia

Circulation

(1998)

A. Fard et al.

Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes

Arterioscler Thromb Vasc Biol

(2000)

J.T. Kielstein et al.

Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects

Circulation

(2003)

Cited by (136)

Asymmetric dimethylarginine positively modulates calcium-sensing receptor signalling to promote lipid accumulation
2023, Cellular Signalling
Asymmetric dimethylarginine (ADMA) is generated through the irreversible methylation of arginine residues. It is an independent risk factor for cardiovascular disease, currently thought to be due to its ability to act as a competitive inhibitor of the nitric oxide (NO) synthase enzymes. Plasma ADMA concentrations increase with obesity and fall following weight loss; however, it is unknown whether they play an active role in adipose pathology. Here, we demonstrate that ADMA drives lipid accumulation through a newly identified NO-independent pathway via the amino-acid sensitive calcium-sensing receptor (CaSR). ADMA treatment of 3T3-L1 and HepG2 cells upregulates a suite of lipogenic genes with an associated increase in triglyceride content. Pharmacological activation of CaSR mimics ADMA while negative modulation of CaSR inhibits ADMA driven lipid accumulation. Further investigation using CaSR overexpressing HEK293 cells demonstrated that ADMA potentiates CaSR signalling via G_q intracellular Ca²⁺ mobilisation. This study identifies a signalling mechanism for ADMA as an endogenous ligand of the G protein-coupled receptor CaSR that potentially contributes to the impact of ADMA in cardiometabolic disease.
Effect of cigarette smoking on serum methylarginine and α-klotho levels
2023, Nutrition, Metabolism and Cardiovascular Diseases
Smoking causes many diseases such as cardiovascular, lung diseases, stroke and premature aging. However, the role of smoking in the pathogenesis of these diseases is unclear. Increasing evidence suggests that methylarginine pathway metabolites and α-klotho may be strong markers for pathologies such as premature aging, endothelial dysfunction, and oxidant damage. Therefore, the study aimed to measure the serum levels of arginine, asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), N-monomethyl-l-arginine (L-NMMA), and α-klotho levels in smokers.
This case-control analytical study included 65 smokers and 71 non-smokers. Sociodemographic characteristics, routine biochemistry parameters, Framingham risk scores and Fagerström Nicotine Dependence Test (FTND) were recorded. Serum methylarginine and α-klotho levels were analyzed by tandem mass spectrometry and enzyme-linked immunosorbent assay (ELISA), respectively. Serum ADMA (p < 0.001), L-NMMA (p = 0.024), SDMA (p < 0.001) levels of smokers were higher than non-smokers, and serum α-klotho (p < 0.001) and arginine levels (p < 0.001) were lower. There was a positive correlation between serum ADMA levels with FNDT, age and pack/year in smokers, while there was a negative correlation between klotho levels and age. A positive correlation was found between serum ADMA levels, Framingham risk score and age in non-smokers.
Smoking is related to premature aging and is a strong risk factor for various diseases such as cardiovascular, inflammatory, and renal diseases. Elevated serum methylarginine and decreased serum klotho levels were found in smokers. Therefore, our findings suggest that smoking may be involved in the pathogenesis of these diseases by affecting α-klotho and methylarginine-related pathways.
The role of prognostic biomarkers and their implications in early detection of preeclampsia: A systematic review
2023, Process Biochemistry
Preeclampsia is a multisystemic condition causing severe implications in mothers and children suffering from proteinuria and gestational hypertension. Globally, there is an upsurge in morbidity and mortality due to preeclampsia and its complications such as hypertension, endothelial dysfunction, various cardiovascular diseases and proteinuria. Research and meta-analysis on preeclampsia are emphasized as complete understanding about its underlying cause remains to be obscure. The occurrence of preeclampsia is indicated by the presence of elevated levels of methylenetetrahydrofolate reductase (MTHFR), homocysteine and asymmetric dimethylarginine (ADMA) which are well known to be associated with risk factors and are therefore considered as prognostic biomarkers for identifying women with preeclampsia at a very early stage. Elevated levels of these biomarkers cause chronic inflammation which impairs endothelial function. Endothelial dysfunction has been notably prominent in studies addressing the complications of preeclampsia such as cardiovascular disease (CVD). Various analytical techniques have been employed in the accurate screening and quantification of these molecules which is crucial in understanding molecular mechanisms underlying the pathophysiology of various preeclamptic complications. The epigenetic modifications in certain genes not only alter the biosynthesis and regulation of MTHFR, homocysteine and ADMA but also act as individual markers leading to conditions that heighten preeclampsia, giving rise to cardiovascular risk during and after preeclampsia. Therefore, multiple biomarkers are often desired because of their synergistic effect to enhance clinical efficiency. This review focuses on the metabolic links between MTHFR, homocysteine and ADMA, their role as preeclampsia risk predictors, their lowering mechanisms, strategies that incorporate multiple markers and their importance over individualistic biomarkers. In conclusion, the use of a multiple biomarker approach with MTHFR SNPs, homocysteine and ADMA can contribute to the advanced prediction of preeclampsia and its complications.
Plasma levels of Asymmetric Di Methyl Arginine and endothelial dysfunction in diabetic subjects with neuropathic foot ulcer
2021, Foot
Asymmetric dimethyl arginine (ADMA) is an amino acid that acts as an endogenous competitive inhibitor of Nitric oxide synthase, leading to endothelial dysfunction (ED). The aim of this study was to evaluate the relationship between plasma ADMA (p-ADMA) level and ED in diabetic subjects with neuropathic foot ulcer (NFU), and the possible predictors of p-ADMA level.
80 diabetic subjects of matched age, sex and BMI were included; 40 with NFU (G1), 20 with peripheral nerve dysfunction (PND) (G2) and 20 without PND (G3), plus 20 matched healthy subjects (G4). Flow-mediated-dilatation (FMD) of brachial artery and Carotid-intima-media-thickness (CIMT) were measured to evaluate ED and subclinical atherosclerosis, respectively.
G1&2 had a significantly lower FMD than G3&4 [−5.09 (−22.5 to 22.92), 4.67 (−15 to 23.91) vs. 15.74 (8.33−36.59) and 20.1 (10.0–46.15)%, respectively] (p < 0.001), and higher CIMT [0.9 (0.6–1.5), 0.9 (0.6–1.3) vs. 0.6 (0.5−0.8) and 0.7 (0.5−0.9) cm, respectively] (p < 0.001, r = 0.237, p = 0.034, r = 0.330, p = 0.003, respectively), with no significant correlation with FMD (r = −0.176, p = 0.118). FMD was inversely and strongly related to CIMT (r = −0.520, p < 0.001). p-ADMA levels were significantly higher in uncontrolled hypertensive patients in comparison to controlled and normotensive subjects [717 (286−3611) vs. 648 (335−874) and 686 (526−857) ng/L, respectively] (p = 0.026). Metformin users and hypertensive subjects on ACEIs or ARBs had the lowest p-ADMA levels than the non-users (p < 0.001, p = 0.007, respectively).
The remarkable ED in diabetic subjects with NFU is unlikely to be due to alteration in p-ADMA. Further studies are needed in order to conclude a causal association between p-ADMA and ED in this group of patients.
Cardiometabolic Antecedents of Preeclampsia
2021, Chesley’s Hypertensive Disorders in Pregnancy
In this chapter, we advance the concept that maternal cardiometabolic factors interact with placental factors to promote inflammation, endothelial cell dysfunction, and the maternal preeclampsia syndrome. We also summarize evidence suggesting that the same underlying factors that contribute to preeclampsia also increase a woman's risk of developing cardiovascular disease (CVD) in later life. The majority of data on candidate factors contributing to preeclampsia have been retrospective in nature, relying on measurements conducted either in early pregnancy, prior to onset of clinical symptoms of preeclampsia, or months to years postpregnancy after clinical symptoms of preeclampsia have resolved (and in the absence of a placenta). Because of the logistical difficulties of recruiting preconception cohorts of women, few studies have investigated cardiovascular risk factors before pregnancy in relation to risk of preeclampsia. Nevertheless, a substantial body of literature on prepregnancy cardiometabolic antecedents of preeclampsia is now available. This updated chapter therefore surveys the available data on cardiometabolic risk factors before conception in relation to risk of preeclampsia. There is evidence for prepregnancy factors potentially related to, and unrelated to, the metabolic syndrome consistent with a heterogeneous etiology of preeclampsia. These data support the hypothesis that chronic, underlying factors present before pregnancy, including metabolic and cardiac antecedents, contribute to both risk of preeclampsia and risk of later-life CVD.
Obesity and asthma
2020, Journal of Allergy and Clinical Immunology
Obesity has been well recognized as an important comorbidity in patients with asthma, representing a unique phenotype and endotype. This association indicates a close relationship between metabolic and inflammatory dysregulation. However, the detailed organ-organ, cellular, and molecular interactions are not completely resolved. Because of that, the relationship between obesity and asthma remains unclear. In this article, clinical and epidemiological studies, as well as data from experimental animal work, are being summarized to provide a state of the art update on this important topic. Much more work is needed, particularly mechanistic, to fully understand the interaction between obesity and asthma and to develop novel preventive and therapeutic strategies.

View all citing articles on Scopus

^☆: Supported by the Norwegian Council for Cardiovascular Diseases, The Norwegian Retail Company RIMI, and Ada og Hagbart Waages Humanitoejre Stiftelse.

View full text

Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine☆

Abstract

Section snippets

Study design and study population

Results

Discussion

J Am Coll Cardiol

Atherosclerosis

Lancet

Biochem Biophys Res Commun

Am J Cardiol

Atherosclerosis

J Am Coll Cardiol

Lancet

Life Sci

Kidney Int

J Am Coll Cardiol

Dietary l-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbitsComparison with lovastatin

Circulation

Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells

J Clin Invest

Nitric oxideAn endogenous modulator of leukocyte adhesion

Proc Natl Acad Sci USA

Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure

Lancet

Biological significance of endogenous methylarginines that inhibit nitric oxide synthases

Cardiovasc Res

LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cellsInvolvement of S-adenosylmethionine-dependent methyltransferases

Circ Res

Impaired nitric oxide synthase pathway in diabetes mellitusRole of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase

Circulation

Oral l-arginine improves endothelial function in healthy individuals older than 70 years

Vasc Med

Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction: Its role in hypercholesterolemia

Circulation

Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes

Arterioscler Thromb Vasc Biol

Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects

Circulation